AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9110067 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir maintenance
Number of subjects: 0
Study 9110067 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study 1937663 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered boiled coffee (caffeine content 860 mg/l)
Number of subjects: 64
Study 1937663 — intervention group
Group type: COMPARATOR
Intervention: Boiled-and-filtered coffee (caffeine content 887 mg/l)
Number of subjects: 64
Study 1937663 — intervention group
Group type: COMPARATOR
Intervention: No coffee (replaced by fruit juice and mineral water)
Number of subjects: 64
Study 6289857 — intervention group
Group type: EXPERIMENTAL
Intervention: MK421 (enalapril maleate)
Number of subjects: 9
Study 6289857 — intervention group
Group type: EXPERIMENTAL
Intervention: MK521
Number of subjects: 9
Study 6289857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31135692 — intervention group
Group type: EXPERIMENTAL
Intervention: REP+EF
Number of subjects: 169
Study 31135692 — intervention group
Group type: COMPARATOR
Intervention: REP+EF/IF
Number of subjects: 169
Study 29329924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (cocoa >85%)
Number of subjects: 19
Study 29329924 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate (cocoa <35%)
Number of subjects: 19
Study 26093823 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (ET)
Number of subjects: 73
Study 26093823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 73
Study 26093823 — intervention group
Group type: COMPARATOR
Intervention: Wait List (WL) Control
Number of subjects: 73
Study 24372004 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg
Number of subjects: 72
Study 22845421 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) session before periodontal treatment
Number of subjects: 44
Study 22845421 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MI session)
Number of subjects: 44
Study 19201327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant (Light Bond fluoride‐releasing sealant, Reliance Orthodontic Products)
Number of subjects: 120
Study 19201327 — intervention group
Group type: COMPARATOR
Intervention: Self-etching primer (Transbond Plus, 3M Unitek)
Number of subjects: 120
Study 19201327 — intervention group
Group type: COMPARATOR
Intervention: Control (no enamel treatment)
Number of subjects: 120
Study 19201327 — intervention group
Group type: COMPARATOR
Intervention: Self-etching primer (SEP)
Number of subjects: 120
Study 19201327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 120
Study 17484067 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg for 3 days)
Number of subjects: 0
Study 17484067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 days)
Number of subjects: 0
Study 15383885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond (octylcyanoacrylate)
Number of subjects: 37
Study 15383885 — intervention group
Group type: COMPARATOR
Intervention: 4.0 Mononylon continuous subcuticular suture
Number of subjects: 37
Study 15383885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Dermabond and suture)
Number of subjects: 37
Study 11799306 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb-sage cream (23 mg/g rhubarb extract, 23 mg/g sage extract)
Number of subjects: 145
Study 11799306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sage cream (23 mg/g sage extract)
Number of subjects: 145
Study 11799306 — intervention group
Group type: COMPARATOR
Intervention: Zovirax cream (50 mg/g aciclovir)
Number of subjects: 145
Study 11799306 — intervention group
Group type: COMPARATOR
Intervention: Zovirax cream
Number of subjects: 145
Study 11799306 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb-sage cream
Number of subjects: 145
Study 9563211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid
Number of subjects: 141
Study 9563211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 141
Study 9563211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 7919069 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (INR 1.5 to 4.0)
Number of subjects: 0
Study 7919069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 0
Study 7919069 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2 - 3)
Number of subjects: 0
Study 7919069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31197107 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 117
Study 31197107 — intervention group
Group type: EXPERIMENTAL
Intervention: RT combined with protein and vitamin supplementation (RTS)
Number of subjects: 117
Study 31197107 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 117
Study 31197107 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20 µg/d)
Number of subjects: 117
Study 28331003 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib 3-16 mg once-daily capsule
Number of subjects: 34
Study 28331003 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib 12 mg
Number of subjects: 34
Study 28331003 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib (any dose)
Number of subjects: 34
Study 26555157 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 25
Study 26555157 — intervention group
Group type: COMPARATOR
Intervention: No-Intervention Control (no-IR)
Number of subjects: 25
Study 23945571 — intervention group
Group type: EXPERIMENTAL
Intervention: IM gentamicin OD and oral amoxicillin twice daily for 7 days
Number of subjects: 2250
Study 23945571 — intervention group
Group type: EXPERIMENTAL
Intervention: IM penicillin and gentamicin OD for 2 days, followed by oral amoxicillin twice daily for 5 days
Number of subjects: 2250
Study 23945571 — intervention group
Group type: COMPARATOR
Intervention: 7 days of once‐daily (OD) intramuscular (IM) procaine penicillin and gentamicin
Number of subjects: 2250
Study 21685374 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily plus Pegylated IFN-α2b 50 μg weekly
Number of subjects: 112
Study 21685374 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg daily monotherapy
Number of subjects: 112
Study 18436182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine spray (0.25 mg)
Number of subjects: 100
Study 18436182 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 100
Study 16494628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (150 mg)
Number of subjects: 303
Study 16494628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 16494628 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (250 mg)
Number of subjects: 303
Study 12931748 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antihistamine (4 times daily)
Number of subjects: 5
Study 12931748 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lodoxamide (4 times daily)
Number of subjects: 5
Study 12931748 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 5
Study 12931748 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.5% (4 times daily)
Number of subjects: 5
Study 12931748 — intervention group
Group type: COMPARATOR
Intervention: Topical cyclosporine compared to topical corticosteroids
Number of subjects: 5
Study 10980901 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard doses of ACE inhibitors
Number of subjects: 0
Study 10980901 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II type I receptor blockade (ARB)
Number of subjects: 0
Study 10980901 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-than-standard doses of ACE inhibitors
Number of subjects: 0
Study 9183781 — intervention group
Group type: EXPERIMENTAL
Intervention: Packy & Marlon (treatment group)
Number of subjects: 59
Study 9183781 — intervention group
Group type: COMPARATOR
Intervention: Entertainment video game (control group)
Number of subjects: 59
Study 8473539 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine rinse for 30 seconds
Number of subjects: 94
Study 8473539 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine rinse for 60 seconds
Number of subjects: 94
Study 8473539 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse for 30 seconds
Number of subjects: 94
Study 3537787 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (24 patients)
Number of subjects: 44
Study 3537787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 patients)
Number of subjects: 44
Study 29680213 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent changes in position (group A)
Number of subjects: 80
Study 29680213 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage (group B)
Number of subjects: 80
Study 29680213 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 80
Study 26016892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise training (H group)
Number of subjects: 14
Study 26016892 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise training (N group)
Number of subjects: 14
Study 25016274 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (Maitland joint mobilization)
Number of subjects: 50
Study 25016274 — intervention group
Group type: COMPARATOR
Intervention: Electrophysical Agents (TENS and cold pack)
Number of subjects: 50
Study 22173575 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazing (at least 100 kcals every 2-3 hours)
Number of subjects: 51
Study 22173575 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazing
Number of subjects: 51
Study 22173575 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study 20719727 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for at least 1 month preoperatively
Number of subjects: 130
Study 20719727 — intervention group
Group type: COMPARATOR
Intervention: No atorvastatin preoperatively
Number of subjects: 130
Study 18812884 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.10 microg/kg/min
Number of subjects: 132
Study 18812884 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.21 microg/kg/min
Number of subjects: 132
Study 18812884 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.13 microg/kg/min
Number of subjects: 132
Study 18812884 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.19 microg/kg/min
Number of subjects: 132
Study 18812884 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.17 microg/kg/min
Number of subjects: 132
Study 15909491 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrofosmin (TF) SPECT imaging
Number of subjects: 19
Study 15909491 — intervention group
Group type: COMPARATOR
Intervention: MIBI SPECT imaging
Number of subjects: 19
Study 12552338 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC at 5.55 GBq/cycle
Number of subjects: 40
Study 12552338 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC at 5.18 GBq/cycle
Number of subjects: 40
Study 12552338 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (lysine +/- arginine)
Number of subjects: 40
Study 12552338 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC at 5 GBq/cycle
Number of subjects: 40
Study 12552338 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed kidney toxicity
Number of subjects: 40
Study 11783197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dachengqi Granule (DCQG)
Number of subjects: 35
Study 11783197 — intervention group
Group type: COMPARATOR
Intervention: Routine western management
Number of subjects: 35
Study 8609343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-alpha levels in patients in functional classes I to III (1.95 +/- 0.54, 2.63 +/- 0.48, 6.4 +/- 1.9 pg/ml)
Number of subjects: 0
Study 8609343 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 levels in patients in functional classes I to III (3.3 +/- 0.55, 6.2 +/- 1.1, 5.22 +/- 0.9 pg/ml)
Number of subjects: 0
Study 8609343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional-hazards analysis for plasma tumor necrosis factor-alpha
Number of subjects: 0
Study 8609343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional-hazards analysis for plasma interleukin-6
Number of subjects: 0
Study 8609343 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of atrial natriuretic factor with circulating tumor necrosis factor-alpha levels
Number of subjects: 0
Study 1938751 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced oscillation technique (infant-adapted)
Number of subjects: 17
Study 6279521 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam/pivampicillin
Number of subjects: 40
Study 6279521 — intervention group
Group type: COMPARATOR
Intervention: pivmecillinam alone
Number of subjects: 40
Study 31888736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo® Wii-based motor activities
Number of subjects: 0
Study 31888736 — intervention group
Group type: COMPARATOR
Intervention: No-Wii motor activities
Number of subjects: 0
Study 29680009 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel spacer placement
Number of subjects: 0
Study 29680009 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel spacer
Number of subjects: 0
Study 27555222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (10 sessions)
Number of subjects: 24
Study 24836122 — intervention group
Group type: EXPERIMENTAL
Intervention: Demanding condition (deliberation about a personal decision problem)
Number of subjects: 0
Study 24836122 — intervention group
Group type: COMPARATOR
Intervention: Nondemanding control condition
Number of subjects: 0
Study 22425616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mere exposure (n=32)
Number of subjects: 104
Study 22425616 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavour-flavour learning (n=33)
Number of subjects: 104
Study 22425616 — intervention group
Group type: COMPARATOR
Intervention: Flavour-nutrient learning (n=39)
Number of subjects: 104
Study 20373924 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 litre of isotonic energy-drink
Number of subjects: 213
Study 20373924 — intervention group
Group type: COMPARATOR
Intervention: Placebo-drink
Number of subjects: 213
Study 18725484 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta(1)-selective adrenergic blocker)
Number of subjects: 25
Study 15944537 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress myocardial perfusion imaging (MPI)
Number of subjects: 16
Study 15944537 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole stress myocardial perfusion imaging (MPI)
Number of subjects: 16
Study 15944537 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress MPI
Number of subjects: 16
Study 15944537 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole stress MPI
Number of subjects: 16
Study 15944537 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress MPI and dipyridamole stress MPI
Number of subjects: 16
Study 12956497 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal cantilever resin‐bonded fixed partial dentures (FPD)
Number of subjects: 60
Study 12956497 — intervention group
Group type: COMPARATOR
Intervention: Bilateral free‐end saddle removable partial dentures (RPD)
Number of subjects: 60
Study 11764120 — intervention group
Group type: EXPERIMENTAL
Intervention: Variglass VLC (polyacid-modified resin) as an occlusal sealant
Number of subjects: 185
Study 8859726 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interleukin‐2 (rIL‐2) at doses of 3.0, 12.0, and 48.0 x 10(6) IU/m(2) i.v. three times weekly (TIW) and recombinant human IL‐4 (rHuIL‐4) at doses of 40, 120, and 400 mu g/m(2) s.c. TIW
Number of subjects: 39
Study 8859726 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interleukin‐2 (rIL‐2)
Number of subjects: 39
Study 8859726 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interleukin‐2 (rIL‐2) and recombinant human IL‐4 (rHuIL‐4)
Number of subjects: 39
Study 1517910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk-specific antibody responses
Number of subjects: 29
Study 1517910 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring casein-specific and beta-lactoglobulin-specific IgE concentrations and IgE/IgG ratios
Number of subjects: 29
Study 1517910 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE-specific antibody concentrations and IgE/IgG-specific ratios for both milk proteins
Number of subjects: 29
Study 1517910 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG1- and IgG4-specific antibody to casein
Number of subjects: 29
Study 1517910 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE/IgG1 and IgE/IgG4 ratios for both casein and beta-lactoglobulin
Number of subjects: 29
Study 1517910 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG-specific concentrations
Number of subjects: 29
Study 6610435 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 90
Study 6610435 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 6610435 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 90
Study 30605922 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT group (n=28)
Number of subjects: 82
Study 29020023 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal anti‐HE intervention (lactulose + branched‐chain amino acids + rifaximin)
Number of subjects: 44
Study 29020023 — intervention group
Group type: COMPARATOR
Intervention: Triple placebos
Number of subjects: 44
Study 26606714 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgment-of-learning (JOL)
Number of subjects: 0
Study 26606714 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing
Number of subjects: 0
Study 26606714 — intervention group
Group type: COMPARATOR
Intervention: Re-study
Number of subjects: 0
Study 25091576 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele (TC + TT genotypes)
Number of subjects: 1075
Study 25091576 — intervention group
Group type: COMPARATOR
Intervention: CC genotype
Number of subjects: 1075
Study 21864417 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (1 g/d)
Number of subjects: 159
Study 21864417 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil (1 g/d)
Number of subjects: 159
Study 21864417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 19386127 — intervention group
Group type: EXPERIMENTAL
Intervention: Celliant socks
Number of subjects: 55
Study 19386127 — intervention group
Group type: COMPARATOR
Intervention: Control socks
Number of subjects: 55
Study 17445520 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg caffeine
Number of subjects: 109
Study 17445520 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free (placebo) solution
Number of subjects: 109
Study 17445520 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine challenge test
Number of subjects: 109
Study 16209965 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg twice daily)
Number of subjects: 5126
Study 16209965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5126
Study 16209965 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 5126
Study 10630938 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 127
Study 10630938 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation
Number of subjects: 127
Study 8936618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gargling with a remote foot pedal-operated gargling apparatus 3 times during daily work over a 3-month period
Number of subjects: 0
Study 8936618 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 0
Study 1409873 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal weights (AbWts)
Number of subjects: 11
Study 1409873 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive muscle training (IMT)
Number of subjects: 11
Study 3909167 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative infection prophylaxis by the 'one-shot' method
Number of subjects: 60
Study 3909167 — intervention group
Group type: COMPARATOR
Intervention: Peri-operative infection prophylaxis for 48-hour duration
Number of subjects: 60
Study 30031679 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM patients
Number of subjects: 102
Study 30031679 — intervention group
Group type: COMPARATOR
Intervention: non-GDM patients
Number of subjects: 102
Study 29671381 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 180
Study 29671381 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 180
Study 29671381 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 180
Study 26873871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Exenatide and Metformin (5 μg Exenatide + 0.5 g MET twice daily for 4 weeks, then 10 μg Exenatide + 0.5 g MET twice daily for 24 weeks)
Number of subjects: 105
Study 23502990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 574
Study 23502990 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 574
Study 20508383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) value of 95-99 mg/dL
Number of subjects: 2207
Study 20508383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) value of 100-104 mg/dL
Number of subjects: 2207
Study 20508383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) value of 105-109 mg/dL
Number of subjects: 2207
Study 20508383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) value of 110-114 mg/dL
Number of subjects: 2207
Study 20508383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) value of 115-119 mg/dL
Number of subjects: 2207
Study 20508383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) value of 120-125 mg/dL
Number of subjects: 2207